You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016300
Aug 20162703
Sep 20161002
Oct 20162203
Nov 20162101
Dec 20162704
Jan 20173203
Feb 20171805
Mar 20174305
Apr 20172803
May 201728015
Jun 201741012
Jul 20173305
Aug 20175808
Sep 201710502
Oct 20175001
Nov 20172604
Dec 20172601
Jan 20182200
Feb 20184701
Mar 20182200
Apr 20184001
May 20182200
Jun 20183902
Jul 20182001
Aug 20182000
Sep 20181602
Oct 20182000
Nov 20181200
Dec 20181200
Jan 20191002
Feb 20191503
Mar 20192200
Apr 2019200
May 20191800
Jun 2019600
Jul 20191900
Aug 2019602
Sep 20191000
Oct 2019400
Nov 20191400
Dec 2019200
Feb 20201200
Mar 20201000
Apr 20201000
May 20201200
Jun 2020800
Jul 20202600
Aug 20201600
Sep 20203000
Oct 20202601
Nov 20201801
Dec 20203000
Jan 2021800
Mar 2021402
Apr 2021200
May 2021300
Aug 2021100
Sep 2021100
Oct 2021400
Nov 2021700
Dec 20211601
Jan 2022600
Feb 20221000
Mar 20222401
Apr 2022900
May 2022800
Jun 20221600
Jul 20221100
Aug 20222801
Sep 20221000
Oct 20221601
Nov 20221201
Dec 2022900
Jan 20231200
Feb 20231101
Mar 2023701
Apr 2023200
May 20231000
Jun 2023400
Jul 2023800
Sep 2023800
Oct 2023200
Nov 2023400
Dec 20231300
Jan 2024200
Feb 2024200
Mar 2024800
Total15140102